Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Pharmacogenetic studies in depression: a proposal for methodologic guidelines

The Pharmacogenomics Journal volume 8, pages 90–100 (2008)Cite this article

Abstract

Pharmacogenetic studies in mood disorders are rapidly proliferating after the initial reports linking gene variants to treatment outcomes. However, a considerable range of methodologies has been used, making it difficult to compare results across studies and limiting the representativeness of findings. Specification of sampling source (inpatients vs outpatients, primary vs tertiary settings), standardization of diagnostic systems and treatments, adequate monitoring of compliance through plasma levels, sufficient length of observation (at least 6 weeks for acute antidepressant treatments, though 3–6 months are preferable), the use of a range of response criteria and the inclusion of possible environmental confounding variables (life events, social support, temperament) are all potentially important issues when planning pharmacogenetic studies. We reviewed the state-of-the-art methodology and suggested possible guideline for future studies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kendler KS . ‘A gene for…’: the nature of gene action in psychiatric disorders. Am J Psychiatry 2005; 162: 1243–1252.

    Article  PubMed  Google Scholar 

  2. Serretti A, Masaki K, De Ronchi D, Kinoshita T . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–257.

    Article  CAS  PubMed  Google Scholar 

  3. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003; 301: 386–389.

    Article  CAS  Google Scholar 

  4. Malhotra AK, Murphy Jr GM, Kennedy JL . Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780–796.

    Article  PubMed  Google Scholar 

  5. Serretti A, Artioli P, Quartesan R . Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 2005; 15: 61–67.

    Article  CAS  PubMed  Google Scholar 

  6. Kendler KS, Gardner Jr CO . Boundaries of major depression: an evaluation of DSM-IV criteria. Am J Psychiatry 1998; 155: 172–177.

    CAS  PubMed  Google Scholar 

  7. Leckman JF, Sholomskas D, Thompson WD, Belanger A, Weissman MM . Best estimate of lifetime psychiatric diagnosis: a methodological study. Arch Gen Psychiatry 1982; 39: 879–883.

    Article  CAS  PubMed  Google Scholar 

  8. Hirschfeld RM, Russell JM, Delgado PL, Fawcett J, Friedman RA, Harrison WM et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998; 59: 669–675.

    Article  CAS  PubMed  Google Scholar 

  9. Goldberg JF, Harrow M, Whiteside JE . Risk for bipolar illness in patients initially hospitalized for unipolar depression. Am J Psychiatry 2001; 158: 1265–1270.

    Article  CAS  PubMed  Google Scholar 

  10. Rice JP, Rochberg N, Endicott J, Lavori PW, Miller C . Stability of psychiatric diagnoses. An application to the affective disorders. Arch Gen Psychiatry 1992; 49: 824–830.

    Article  CAS  PubMed  Google Scholar 

  11. Tsuang M, Faraone S . The Genetics of Mood Disorders. The Johns Hopkins University Press: Baltimore, 1990.

    Google Scholar 

  12. Zimmerman M, Mattia JI, Posternak MA . Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159: 469–473.

    Article  PubMed  Google Scholar 

  13. Meyers BS, Sirey JA, Bruce M, Hamilton M, Raue P, Friedman SJ et al. Predictors of early recovery from major depression among persons admitted to community-based clinics: an observational study. Arch Gen Psychiatry 2002; 59: 729–735.

    Article  PubMed  Google Scholar 

  14. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A . Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25: 1171–1180.

    Article  CAS  PubMed  Google Scholar 

  15. Keller MB, Lavori PW, Mueller TI, Endicott J, Coryell W, Hirschfeld RM et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 1992; 49: 809–816.

    Article  CAS  PubMed  Google Scholar 

  16. Keller MB . Long-term treatment of recurrent and chronic depression. J Clin Psychiatry 2001; 62(Suppl 24): 3–5.

    PubMed  Google Scholar 

  17. Fava M . Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649–659.

    Article  PubMed  Google Scholar 

  18. Serretti A, Zanardi R, Mandelli L, Smeraldi E, Colombo C . A neural network model for combining clinical predictors of antidepressant response in mood disorders. J Affect Disord 2007; 98: 239–245.

    Article  CAS  PubMed  Google Scholar 

  19. Serretti A, Olgiati P, Liebman MN, Hu H, Zhang Y, Zanardi R et al. Clinical prediction of antidepressant response in mood disorders: linear multivariate vs neural network models. Psychiatry Res, (In press).

  20. Winterer G, Ziller M, Linden M . Classification of observational data with artificial neural networks versus discriminant analysis in pharmacoepidemiological studies—can outcome of fluoxetine treatment be predicted? Pharmacopsychiatry 1998; 31: 225–231.

    Article  CAS  PubMed  Google Scholar 

  21. Krishnan KR . Comorbidity and depression treatment. Biol Psychiatry 2003; 53: 701–706.

    Article  PubMed  Google Scholar 

  22. Murrell SA, Himmelfarb S, Wright K . Prevalence of depression and its correlates in older adults. Am J Epidemiol 1983; 117: 173–185.

    Article  CAS  PubMed  Google Scholar 

  23. Bagby RM, Ryder AG, Cristi C . Psychosocial and clinical predictors of response to pharmacotherapy for depression. J Psychiatry Neurosci 2002; 27: 250–257.

    PubMed  PubMed Central  Google Scholar 

  24. Sullivan LE, Fiellin DA, O'Connor PG . The prevalence and impact of alcohol problems in major depression: a systematic review. Am J Med 2005; 118: 330–341.

    Article  PubMed  Google Scholar 

  25. Small GW, Birkett M, Meyers BS, Koran LM, Bystritsky A, Nemeroff CB . Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine collaborative study group. J Am Geriatr Soc 1996; 44: 1220–1225.

    Article  CAS  PubMed  Google Scholar 

  26. Wells CE . Pseudodementia. Am J Psychiatry 1979; 136: 895–900.

    Article  CAS  PubMed  Google Scholar 

  27. Bulbena A, Berrios GE . Pseudodementia: facts and figures. Br J Psychiatry 1986; 148: 87–94.

    Article  CAS  PubMed  Google Scholar 

  28. Keller MB, Lavori PW, Endicott J, Coryell W, Klerman GL . ‘Double depression’: two-year follow-up. Am J Psychiatry 1983; 140: 689–694.

    Article  CAS  PubMed  Google Scholar 

  29. Frank E, Cyranowski JM, Rucci P, Shear MK, Fagiolini A, Thase ME et al. Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder. Arch Gen Psychiatry 2002; 59: 905–911.

    Article  PubMed  Google Scholar 

  30. Zimmerman M, Chelminski I, Posternak MA . Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005; 162: 1370–1372.

    Article  PubMed  Google Scholar 

  31. Rotondo A, Mazzanti C, Dell'Osso L, Rucci P, Sullivan P, Bouanani S et al. Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 2002; 159: 23–29.

    Article  PubMed  Google Scholar 

  32. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE . Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62: 593–602.

    Article  PubMed  Google Scholar 

  33. Corruble E, Ginestet D, Guelfi JD . Comorbidity of personality disorders and unipolar major depression: a review. J Affect Disord 1996; 37: 157–170.

    Article  CAS  PubMed  Google Scholar 

  34. Newton-Howes G, Tyrer P, Johnson T . Personality disorder and the outcome of depression: meta-analysis of published studies. Br J Psychiatry 2006; 188: 13–20.

    Article  PubMed  Google Scholar 

  35. Pilkonis PA, Frank E . Personality pathology in recurrent depression: nature, prevalence, and relationship to treatment response. Am J Psychiatry 1988; 145: 435–441.

    Article  CAS  PubMed  Google Scholar 

  36. Shea MT, Widiger TA, Klein MH . Comorbidity of personality disorders and depression: implications for treatment. J Consult Clin Psychol 1992; 60: 857–868.

    Article  CAS  PubMed  Google Scholar 

  37. Reich JH, Green AI . Effect of personality disorders on outcome of treatment. J Nerv Ment Dis 1991; 179: 74–82.

    Article  CAS  PubMed  Google Scholar 

  38. Sato T, Sakado K, Sato S . Is there any specific personality disorder or personality disorder cluster that worsens the short-term treatment outcome of major depression? Acta Psychiatr Scand 1993; 88: 342–349.

    Article  CAS  PubMed  Google Scholar 

  39. Kool S, Schoevers R, de Maat S, Van R, Molenaar P, Vink A et al. Efficacy of pharmacotherapy in depressed patients with and without personality disorders: a systematic review and meta-analysis. J Affect Disord 2005; 88: 269–278.

    Article  CAS  PubMed  Google Scholar 

  40. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Sullivan PF, Cloninger RC . Borderline personality disorder in major depression: symptomatology, temperament, character, differential drug response, and 6-month outcome. Compr Psychiatry 2003; 44: 35–43.

    Article  PubMed  Google Scholar 

  41. Mulder RT . Personality pathology and treatment outcome in major depression: a review. Am J Psychiatry 2002; 159: 359–371.

    Article  PubMed  Google Scholar 

  42. Russell JM, Kornstein SG, Shea MT, McCullough JP, Harrison WM, Hirschfeld RM et al. Chronic depression and comorbid personality disorders: response to sertraline versus imipramine. J Clin Psychiatry 2003; 64: 554–561.

    Article  CAS  PubMed  Google Scholar 

  43. Joyce PR, Mulder RT, Cloninger CR . Temperament predicts clomipramine and desipramine response in major depression. J Affect Disord 1994; 30: 35–46.

    Article  CAS  PubMed  Google Scholar 

  44. Joffe RT, Bagby RM, Levitt AJ, Regan JJ, Parker JD . The tridimensional personality questionnaire in major depression. Am J Psychiatry 1993; 150: 959–960.

    Article  CAS  PubMed  Google Scholar 

  45. Ebstein RP . The molecular genetic architecture of human personality: beyond self-report questionnaires. Mol Psychiatry 2006; 11: 427–445.

    Article  CAS  PubMed  Google Scholar 

  46. Serretti A, Mandelli L, Lorenzi C, Landoni S, Calati R, Insacco C et al. Temperament and character in mood disorders: influence of DRD4, SERTPR, TPH and MAO-A polymorphisms. Neuropsychobiology 2006; 53: 9–16.

    Article  CAS  PubMed  Google Scholar 

  47. Millon T, Davis RD . Disorders of Personality: DSM-IV and Beyond, 2nd edn. John Wiley: Toronto, CA, USA, 1995.

    Google Scholar 

  48. Battaglia M, Przybeck TR, Bellodi L, Cloninger CR . Temperament dimensions explain the comorbidity of psychiatric disorders. Compr Psychiatry 1996; 37: 292–298.

    Article  CAS  PubMed  Google Scholar 

  49. Nierenberg AA . Predictors of response to antidepressants general principals and clinical implications. Psychiatr Clin North Am 2003; 26: 345–352.

    Article  PubMed  Google Scholar 

  50. Esposito K, Goodnick P . Predictors of response in depression. Psychiatr Clin North Am 2003; 26: 353–365.

    Article  PubMed  Google Scholar 

  51. Zanardi R, Cusin C, Rossini D, De Ronchi D, Serretti A . Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression. J Clin Psychopharmacol 2003; 23: 535–539.

    Article  CAS  PubMed  Google Scholar 

  52. Ezquiaga E, Garcia A, Bravo F, Pallares T . Factors associated with outcome in major depression: a 6-month prospective study. Soc Psychiatry Psychiatr Epidemiol 1998; 33: 552–557.

    Article  CAS  PubMed  Google Scholar 

  53. O'Leary D, Costello F, Gormley N, Webb M . Remission onset and relapse in depression. An 18-month prospective study of course for 100 first admission patients. J Affect Disord 2000; 57: 159–171.

    Article  CAS  PubMed  Google Scholar 

  54. Serretti A, Kato M, De Ronchi D, Kinoshita T . Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247–257.

    Article  CAS  PubMed  Google Scholar 

  55. Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Howland RH et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord 1999; 55: 149–157.

    Article  CAS  PubMed  Google Scholar 

  56. Koenig HG, George LK, Peterson BL . Religiosity and remission of depression in medically ill older patients. Am J Psychiatry 1998; 155: 536–542.

    Article  CAS  PubMed  Google Scholar 

  57. Koenig HG, Cohen HJ, Blazer DG, Pieper C, Meador KG, Shelp F et al. Religious coping and depression among elderly, hospitalized medically ill men. Am J Psychiatry 1992; 149: 1693–1700.

    Article  CAS  PubMed  Google Scholar 

  58. Moncrieff J . A comparison of antidepressant trials using active and inert placebos. Int J Methods Psychiatr Res 2003; 12: 117–127.

    Article  PubMed  Google Scholar 

  59. Mandelli L, Serretti A, Colombo C, Florita M, Santoro A, Rossini D et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci 2006; 60: 598–604.

    Article  PubMed  Google Scholar 

  60. Papakostas GI, Petersen T, Mischoulon D, Hughes ME, Spector AR, Alpert JE et al. Functioning and interpersonal relationships as predictors of response in treatment-resistant depression. Compr Psychiatry 2003; 44: 44–50.

    Article  PubMed  Google Scholar 

  61. Hoglend P, Perry JC . Defensive functioning predicts improvement in major depressive episodes. J Nerv Ment Dis 1998; 186: 238–243.

    Article  CAS  PubMed  Google Scholar 

  62. Dew MA, Reynolds CF, Houck PR, Hall M, Buysse DJ, Frank E et al. Temporal profiles of the course of depression during treatment—predictors of pathways toward recovery in the elderly. Arch Gen Psychiatry 1997; 54: 1016–1024.

    Article  CAS  PubMed  Google Scholar 

  63. Murphy Jr GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF . Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004; 61: 1163–1169.

    Article  CAS  PubMed  Google Scholar 

  64. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American psychiatric association. Am J Psychiatry 2000; 157: 1–45.

    Article  Google Scholar 

  65. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ . World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002; 3: 5–43.

    Article  PubMed  Google Scholar 

  66. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J . Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354–359.

    Article  CAS  PubMed  Google Scholar 

  67. Adli M, Baethge C, Heinz A, Langlitz N, Bauer M . Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387–400.

    Article  PubMed  Google Scholar 

  68. Lotrich FE, Bies RR, Smith GS, Pollock BG . Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 2006; 20: 33–40.

    Article  PubMed  Google Scholar 

  69. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG . Quantitative rating of depressive states. Acta Psychiatr Scand 1975; 51: 161–170.

    Article  CAS  PubMed  Google Scholar 

  70. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH . The inventory of depressive symptomatology (IDS): psychometric properties. Psychol Med 1996; 26: 477–486.

    Article  CAS  PubMed  Google Scholar 

  71. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T et al. The inventory of depressive symptomatology, clinician rating (IDS-C) and self-report (IDS-SR), and the quick inventory of depressive symptomatology, clinician rating (QIDS-C) and self-report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 2004; 34: 73–82.

    Article  CAS  PubMed  Google Scholar 

  72. Hamilton M . Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–296.

    Article  CAS  PubMed  Google Scholar 

  73. Montgomery SA, Asberg M . A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–389.

    Article  CAS  Google Scholar 

  74. Mulder RT, Joyce PR, Frampton C . Relationships among measures of treatment outcome in depressed patients. J Affect Disord 2003; 76: 127–135.

    Article  PubMed  Google Scholar 

  75. Bech P, Malt U, Dencker S, Ahlfors U, Elgen K, Lewander T et al. Scales for assessment of diagnosis and severity of mental disorders. Acta Psychiatr Scand 1993; 87(Suppl 372): 37–40.

    Google Scholar 

  76. Serretti A, Lattuada E, Zanardi R, Franchini L, Smeraldi E . Patterns of symptom improvement during antidepressant treatment of delusional depression. Psychiatry Res 2000; 94: 185–190.

    Article  CAS  PubMed  Google Scholar 

  77. Quitkin FM, Rabkin JD, Markowitz JM, Stewart JW, McGrath PJ, Harrison W . Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry 1987; 44: 259–264.

    Article  CAS  PubMed  Google Scholar 

  78. Quitkin FM, McGrath PJ, Rabkin JG, Stewart JW, Harrison W, Ross DC et al. Different types of placebo response in patients receiving antidepressants. Am J Psychiatry 1991; 148: 197–203.

    CAS  PubMed  Google Scholar 

  79. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55: 334–343.

    Article  CAS  PubMed  Google Scholar 

  80. Peters EJ, Slager SL, McGrath PJ, Knowles JA, Hamilton SP . Investigation of serotonin-related genes in antidepressant response. Mol Psychiatry 2004; 9: 879–889.

    Article  CAS  PubMed  Google Scholar 

  81. Rausch JL, Johnson ME, Fei Y-J, Li JQ, Shendarkar N, Mac Hobby H et al. Initial conditions of serotonin transporter kinetics and genotype: influence on ssri treatment trial outcome. Biol Psychiatry 2002; 51: 723–732.

    Article  CAS  PubMed  Google Scholar 

  82. Mitchell AJ . Two-week delay in onset of action of antidepressants: new evidence. Br J Psychiatry 2006; 188: 105–106.

    Article  PubMed  Google Scholar 

  83. Posternak MA, Zimmerman M . Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry 2005; 66: 148–158.

    Article  CAS  PubMed  Google Scholar 

  84. Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–590.

    Article  CAS  PubMed  Google Scholar 

  85. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB . The serotonin transporter polymorphism, 5-HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004; 174: 525–529.

    Article  CAS  Google Scholar 

  86. Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 2004; 25: 119–142.

    Article  PubMed  Google Scholar 

  87. Donovan SJ, Quitkin FM, Stewart JW, Ocepek-Welikson K, Harrison W, McGrath PJ et al. Duration of antidepressant trials: clinical and research implications. J Clin Psychopharmacol 1994; 14: 64–66.

    Article  CAS  PubMed  Google Scholar 

  88. Adli M, Bauer M, Rush AJ . Algorithms and collaborative-care systems for depression: are they effective and why? A systematic review. Biol Psychiatry 2006; 59: 1029–1038.

    Article  PubMed  Google Scholar 

  89. Adli M, Rush AJ, Moller HJ, Bauer M . Algorithms for optimizing the treatment of depression: making the right decision at the right time. Pharmacopsychiatry 2003; 36(Suppl 3): S222–S229.

    PubMed  Google Scholar 

  90. Mann JJ . The medical management of depression. N Engl J Med 2005; 353: 1819–1834.

    Article  CAS  PubMed  Google Scholar 

  91. Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ et al. Clinical results for patients with major depressive disorder in the Texas medication algorithm project. Arch Gen Psychiatry 2004; 61: 669–680.

    Article  PubMed  Google Scholar 

  92. Aitchison K, Huezo-Diaz P, Williamson R, Hoda F, Nash M, Rietschel M et al. Genetic Association Data from Gendep, a Multicentre European Study. XIVth World Congress of Psychiatric Genetics. American Journal of Medical Genetics, Neuropsychiatry Genetics: Cagliari, Itlay, 2006, p 690.

    Google Scholar 

  93. Gibbons RD, Hedeker D, Elkin I, Waternaux C, Kraemer HC, Greenhouse JB et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. application to the NIMH treatment of depression collaborative research program dataset. Arch Gen Psychiatry 1993; 50: 739–750.

    Article  CAS  PubMed  Google Scholar 

  94. Hedeker D, Gibbons RD . MIXREG: a computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Programs Biomed 1996; 49: 229–252.

    Article  CAS  PubMed  Google Scholar 

  95. Serretti A, Smeraldi E . Neural network analysis in pharmacogenetics of mood disorders. BMC Med Genet 2004; 5: 27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Licinio J, Wong ML . Pharmacogenomics in psychiatry: genomic considerations. Mol Psychiatry 2005; 10: 713.

    Article  CAS  PubMed  Google Scholar 

  97. Cardon LR, Bell JI . Association study designs for complex diseases. Nat Rev Genet 2001; 2: 91–99.

    Article  CAS  PubMed  Google Scholar 

  98. Kelly PJ, Stallard N, Whittaker JC . Statistical design and analysis of pharmacogenetic trials. Stat Med 2005; 24: 1495–1508.

    Article  PubMed  Google Scholar 

  99. Serretti A, Macciardi F, Cusin C, Lattuada E, Lilli R, Di Bella D et al. No interaction of GABA(A) alpha-1 subunit and dopamine receptor D4 exon 3 genes in symptomatology of major psychoses. Am J Med Genet 1999; 88: 44–49.

    Article  CAS  PubMed  Google Scholar 

  100. Lerer B, Macciardi F, Segman RH, Adolfsson R, Blackwood D, Blairy S et al. Variability of 5-HT2C receptor cys23ser polymorphism among European populations and vulnerability to affective disorder. Mol Psychiatry 2001; 6: 579–585.

    Article  CAS  PubMed  Google Scholar 

  101. Pritchard JK, Rosenberg NA . Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220–228.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Tsapakis E, Basu A, Aitchison K . Transcriptomics and proteomics: advancing the understanding of psychiatric pharmacogenomics. Clin Neuropsychiatry 2004; 1: 117–124.

    Google Scholar 

  103. van Rossum EFC, Binder EB, Majer M, Koper JW, Ising M, Modell S et al. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006; 59: 681–688.

    Article  CAS  PubMed  Google Scholar 

  104. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 2004; 36: 1319–1325.

    Article  CAS  PubMed  Google Scholar 

  105. Curtis D, Sham PC . Estimated haplotype counts from case–control samples cannot be treated as observed counts. Am J Hum Genet 2006; 78: 729–730.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Serretti A, Artioli P . Ethical problems in pharmacogenetic studies of psychiatric disorders. Pharmacogenom J 2006; 6: 289–295.

    Article  CAS  Google Scholar 

  107. Arias B, Catalan R, Gasto C, Gutierrez B, Fananas L . 5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study. J Clin Psychopharmacol 2003; 23: 563–567.

    Article  CAS  PubMed  Google Scholar 

  108. Hong CJ, Chen TJ, Yu YW, Tsai SJ . Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenom J 2006; 6: 27–33.

    Article  CAS  Google Scholar 

  109. Joyce PR, Mulder RT, Luty SE, McKenzie JM, Miller AL, Rogers GR et al. Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline. Int J Neuropsychopharmacol 2003; 6: 339–346.

    Article  CAS  PubMed  Google Scholar 

  110. Kato M, Ikenaga Y, Wakeno M, Okugawa G, Nobuhara K, Fukuda T et al. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism. Int Clin Psychopharmacol 2005; 20: 151–156.

    Article  PubMed  Google Scholar 

  111. Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 2006; 53: 186–195.

    Article  CAS  PubMed  Google Scholar 

  112. Kim DK, Lim SW, Lee S, Sohn SE, Kim S, Hahn CG et al. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215–219.

    Article  CAS  PubMed  Google Scholar 

  113. Kim H, Lim SW, Kim S, Kim JW, Chang YH, Carroll BJ et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 2006; 296: 1609–1618.

    Article  CAS  PubMed  Google Scholar 

  114. Kirchheiner J, Nickchen K, Sasse J, Bauer M, Roots I, Brockmoller J . A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment. Pharmacogenom J 2006.

  115. Kraft JB, Slager SL, McGrath PJ, Hamilton SP . Sequence analysis of the serotonin transporter and associations with antidepressant response. Biol Psychiatry 2005; 58: 374–381.

    Article  CAS  PubMed  Google Scholar 

  116. Lee MS, Lee HY, Lee HJ, Ryu SH . Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr Genet 2004; 14: 111–115.

    Article  PubMed  Google Scholar 

  117. Minov C, Baghai TC, Schule C, Zwanzger P, Schwarz MJ, Zill P et al. Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression. Neurosci Lett 2001; 303: 119–122.

    Article  CAS  PubMed  Google Scholar 

  118. Serretti A, Cusin C, Rossini D, Artioli P, Dotoli D, Zanardi R . Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders. Am J Med Genet 2004; 129B: 36–40.

    Article  PubMed  Google Scholar 

  119. Smeraldi E, Zanardi R, Benedetti F, Dibella D, Perez J, Catalano M . Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998; 3: 508–511.

    Article  CAS  PubMed  Google Scholar 

  120. Yoshida K, Ito K, Sato K, Takahashi H, Kamata M, Higuchi H et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 383–386.

    Article  CAS  PubMed  Google Scholar 

  121. Yoshida K, Takahashi H, Higuchi H, Kamata M, Ito K, Sato K et al. Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms. Am J Psychiatry 2004; 161: 1575–1580.

    Article  PubMed  Google Scholar 

  122. Yu YW, Tsai SJ, Chen TJ, Lin CH, Hong CJ . Association study of the serotonin transporter promoter polymorphism and symptomatology and antidepressant response in major depressive disorders. Mol Psychiatry 2002; 7: 1115–1119.

    Article  CAS  PubMed  Google Scholar 

  123. Zanardi R, Benedetti F, DiBella D, Catalano M, Smeraldi E . Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of serotonin transporter gene. J Clin Psychopharmacol 2000; 20: 105–107.

    Article  CAS  PubMed  Google Scholar 

  124. Zanardi R, Serretti A, Rossini D, Franchini L, Cusin C, Lattuada E et al. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol Psychiatry 2001; 50: 323–330.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Psychiatry, University of Bologna, Bologna, Italy

    A Serretti & M Kato

  2. Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan

    M Kato

  3. Neurogenetics Section, Centre for Addiction and Mental Health (CAMH), University of Toronto,

    J L Kennedy

  4. Toronto, Ontario, Canada

    J L Kennedy

Authors
  1. A Serretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J L Kennedy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Serretti.

Additional information

Duality of interest

No conflict of interest or financial support is present for the authors.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Serretti, A., Kato, M. & Kennedy, J. Pharmacogenetic studies in depression: a proposal for methodologic guidelines. Pharmacogenomics J 8, 90–100 (2008). https://doi.org/10.1038/sj.tpj.6500477

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.tpj.6500477

Keywords

This article is cited by

Search

Advanced search

Quick links